Walleye Trading’s Protalix BioTherapeutics PLX Stock Holding History

Walleye Trading’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-81,000	Closed	-$108K	–	5741
2021 Q3	$108K	Sell	81,000 -54,000	-40%	-$82.1K	﹤0.01%	4319
2021 Q2	$258K	Buy	+135,000	New	+$465K	﹤0.01%	3667
2020 Q3	–	Sell	-36,979	Closed	-$140K	–	4499
2020 Q2	$140K	Buy	+36,979	New	+$126K	﹤0.01%	3315

Other funds holding PLX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Walleye Trading's PLX Position: Q4 2021 in Review

Walleye Trading sold out of Protalix BioTherapeutics (PLX) in Q4 2021, closing a stake of 81,000 shares — an estimated $108K sold.

Walleye Trading first reported a position in PLX in Q2 2020 and held it in 3 quarters. The position peaked at $258K in Q2 2021. 31 funds tracked by Wall St. Rank hold PLX as of Q4 2021.

Walleye Trading reported no remaining Protalix BioTherapeutics position as of Q4 2021 after selling out during the quarter.
Walleye Trading sold 81,000 Protalix BioTherapeutics shares in Q4 2021, an estimated $108K.
Walleye Trading first reported a position in Protalix BioTherapeutics in Q2 2020 and held it in 3 quarters.
Walleye Trading's Protalix BioTherapeutics position peaked at $258K in Q2 2021.
31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2021.

Based on Walleye Trading's 13F filing for Q4 2021, filed 14 Feb 2022.